CLLS Cellectis

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLLS

Price (delayed)

$3.09

Market cap

$224.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$298.1M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 34

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene ...

Highlights
The company's debt fell by 9% QoQ
The company's EPS rose by 2.9% YoY
The company's gross profit rose by 37% YoY but it fell by 6% QoQ
The revenue is up by 37% YoY but it is down by 6% from the previous quarter
CLLS's equity is down by 48% year-on-year and by 21% since the previous quarter
CLLS's net income is down by 11% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cellectis.com
Peers: QURE NVAX REGN

Key stats

What are the main financial stats of CLLS

CLLS stock price

How has the Cellectis stock price performed over time
Intraday
0%
1 week
-14.88%
1 month
-16.49%
1 year
116.08%
YTD
-36.16%
QTD
-2.52%

Financial performance

How have Cellectis's revenue and profit performed over time
Revenue
$75.11M
Gross profit
$75.11M
Operating income
-$44.07M
Net income
-$67.23M
Gross margin
100%
Net margin
-89.5%
Cellectis's operating margin has decreased by 41% from the previous quarter but it has increased by 39% YoY
The company's gross profit rose by 37% YoY but it fell by 6% QoQ
The revenue is up by 37% YoY but it is down by 6% from the previous quarter
The company's operating income fell by 33% QoQ but it rose by 17% YoY

Price vs fundamentals

How does CLLS's price correlate with its fundamentals

Growth

What is Cellectis's growth rate over time

Valuation

What is Cellectis stock price valuation
P/E
N/A
P/B
3.73
P/S
4.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
The company's EPS rose by 2.9% YoY
The P/B is 133% more than the 5-year quarterly average of 1.6 and 29% more than the last 4 quarters average of 2.9
CLLS's equity is down by 48% year-on-year and by 21% since the previous quarter
The price to sales (P/S) is 58% lower than the 5-year quarterly average of 9.8 but 15% higher than the last 4 quarters average of 3.6
The revenue is up by 37% YoY but it is down by 6% from the previous quarter

Efficiency

How efficient is Cellectis business performance
The company's return on sales has shrunk by 111% QoQ but it rose by 16% YoY
CLLS's return on invested capital has dropped by 89% since the previous quarter but it is up by 9% year-on-year
The return on equity has dropped by 75% year-on-year and by 16% since the previous quarter
CLLS's ROA is down by 31% year-on-year and by 5% since the previous quarter

Dividends

What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLLS.

Financial health

How did Cellectis financials performed over time
CLLS's total assets is 26% greater than its total liabilities
CLLS's total assets is down by 21% year-on-year and by 11% since the previous quarter
CLLS's quick ratio is down by 10% year-on-year and by 6% since the previous quarter
The company's debt is 81% higher than its equity
CLLS's debt to equity has soared by 93% year-on-year and by 15% since the previous quarter
CLLS's equity is down by 48% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.